The current financial score of Vanda Pharmaceuticals Inc is 6.32. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 69.81M, representing a year-over-year increase of 24.10%, while its net profit experienced a year-over-year increase of 0.11%.
The current valuation score of Vanda Pharmaceuticals Inc is 8.12. Its current P/E ratio is -0.93, which is -11377.24% below the recent high of 105.42 and -8071.77% above the recent low of -76.39.
The current earnings forecast score of Vanda Pharmaceuticals Inc is 8.00. The average price target is 11.50, with a high of 20.00 and a low of 4.50.
The current price momentum score of Vanda Pharmaceuticals Inc is 3.88. Currently, the stock price is trading between the resistance level at 4.37 and the support level at 3.48, making it suitable for range-bound swing trading.
The current institutional shareholding score of Vanda Pharmaceuticals Inc is 7.00. The latest institutional shareholding proportion is 78.40%, representing a quarter-over-quarter increase of 1.13%.
The current risk assessment score of Vanda Pharmaceuticals Inc is 5.61. The company's beta value is 0.63. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.